Identification of CLUAP1 as a human osteosarcoma tumor-associated antigen recognized by the humoral immune system

International Journal of Oncology

Volumn 30, Issue 2, 2007, Pages 461-467

  Ishikura, Hisamitsu ^a,d   Ikeda, Hiroaki ^a   Abe, Hiroyuki ^a   Ohkuri, Takayuki ^a   Hiraga, Hiroaki ^b   Isu, Kazuo ^b   Tsukahara, Tomohide ^c   Sato, Noriyuki ^c   Kitamura, Hidemitsu ^a   Iwasaki, Norimasa ^d   Takeda, Naoki ^a   Minami, Akio ^d   Nishimura, Takashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO CANCER CENTER   (Japan)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Osteosarcoma; SEREX; Tumor associated antigen

Indexed keywords

CLUSTERIN ASSOCIATED PROTEIN 1, HUMAN; CLUSTERIN-ASSOCIATED PROTEIN 1, HUMAN; COMPLEMENTARY DNA; MESSENGER RNA; RECOMBINANT PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHEMISTRY; CHILD; FEMALE; GENE EXPRESSION REGULATION; GENE LIBRARY; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; MALE; METABOLISM; MOLECULAR CLONING; OSTEOSARCOMA; PHYSIOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ADOLESCENT; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CHILD; CLONING, MOLECULAR; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE LIBRARY; HUMANS; IMMUNE SYSTEM; MALE; OSTEOSARCOMA; PROGNOSIS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE DISTRIBUTION;

EID: 34047255598     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Birch JM, Alston RD, Quinn M and Kelsey AM: Incidence of malignant disease by morphological type in young persons aged 12-24 years in England, 1979-1997. Eur J Cancer 39: 2622-2631, 2003.
2. Bruland OS and Pihl A: On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 33: 1725-1731, 1997.
3. Bacci G, Briccoli A, Ferrari S, et al: Neoadjuvant chemotherapy for osteosarcoma of extremity. Long-term results of the Rizzoli's 4th protocol. Eur J Cancer 37: 2030-2039, 2001.
4. Boon T and Old LJ: Cancer tumor antigens. Curr Opin Immunol 9: 681-683, 1997.
5. Kawakami Y, Fujita T, Matsuzaki Y, et al: Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 95: 784-791, 2004.
6. Wang R-F and Rosenberg SA: Human tumor antigens for cancer vaccine development. Immunol Rev 170: 85-100, 1999.
7. Sudo T, Kuramoto T, Komiya S, Inoue A and Itoh K: Expression of MAGE genes in osteosarcoma. J Orthop Res 15: 128-132, 1997.
8. Ishida H, Komiya S, Inoue Y, Yutani S, Inoue A and Itoh K: Expression of the SART1 tumor-rejection antigen in human osteosarcomas. Int J Oncol 17: 29-32, 2000.
9. Tsuda N, Murayama K, Ishida H, et al: Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides. J Orthop Res 19: 346-351, 2001.
10. Tsukahara T, Nabeta Y, Kawaguchi S, et al: Identification of human autologous cytotoxic T-lymphocyte defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res 64: 5442-5448, 2004.
11. + T cell response in antitumor immunity. Curr Opin Immunol 10: 588-594, 1998.
12. Nishimura T, Nakui M, Sato M, et al: The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 46: S52-S61, 2000.
13. Sahin U, Türeci Ö, Schmitt H, et al: Human neoplasms elicit multiple specific immune response in the autologous host. Proc Natl Acad Sci USA 92: 11810-11813, 1995.
14. Li G, Miles A, Line A and Rees RC: Identification of tumor antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother 53: 139-143, 2004.
15. Old LJ and Chen Y-T: New paths in human cancer serology. J Exp Med 187: 1163-1167, 1998.
16. Brichard V, Van Pel A, Wolfel T, et al: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocyts on HLA-A2 melanomas. J Exp Med 178: 489-495, 1993.
17. van der Bruggen P, Szikora JP, Boel P, et al: Autologous cytolytic T lymphocytes recognize a MAGE-1 non-apeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol 24: 2134-2140, 1994.
18. Yoshida N, Abe H, Ohkuri T, et al: Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol 28: 1089-1098, 2006.
19. Hellwinkel OJ, Müller J, Pollmann A and Kabisch H: Osteosarcoma cell lines display variable individual reactions on wildtype p53 and Rb tumor-suppressor transgenes. J Gene Med 7: 407-419, 2005.
20. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature 411: 380-384, 2001.
21. Slovin SF, Lackman RD, Ferrone S, Mastrangelo MJ and Kiely PE: Cellular immune response to human sarcoma: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J Immunol 137: 3042-3048, 1986.
22. Nabeta Y, Kawaguchi S, Sahara H, et al: Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line. J Orthop Sci 8: 554-559, 2003.
23. Sato Y, Nabeta Y, Tsukahara T, et al: Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J Immunol 169: 1611-1618, 2002.
24. Worley BS, van den Broeke LT, Goletz TJ, et al: Antigenicity of fusion protein from sarcoma-associates chromosomal translocations. Cancer Res 61: 6868-6875, 2001.
25. Trieb K, Lehnert R, Stulnig T, Sulzbacher I and Shroyer R: Survivin expression in human osteosarcoma is a maker for survival. Eur J Surg Oncol 29: 379-382, 2003.
26. Wang W, Luo H and Wang A: Expression of survivin and correlation with PCNA in osteosarcoma. J Surg Oncol 93: 578-584, 2006. (Pubitemid 43806994)
27. Naka N, Araki N, Nakanishi H, et al: Expression of SSX gene in human osteosarcoma. Int J Cancer 98: 640-642, 2002.
28. Takahashi M, Lin Y, Nakamura Y and Furukawa Y: Isolation and characterization of a novel gene CLUAP1 whose expression is frequently upregulated in colon cancer. Oncogene 23: 9289-9294, 2004.
29. Chen X, Halberg RB, Ehrhardt WM, Torrealba J and Dove WF: Clusterin as a biomarker in murine and human intestinal neoplasia. Proc Natl Acad Sci USA 100: 9530-9535, 2003.
30. Lohrisch C and Piccart M: An overview of HER2. Semin Oncol 28: 3-11, 2001.
31. Hough CD, Cho KR, Zonderman AB, Schwartz DR and Morin PJ: Coordinately up-regulated genes in ovarian cancer. Cancer Res 61: 3869-3876, 2001.
32. Jinawath N, Furukawa Y and Nakamura Y: Identification of NOL8, a nuclear protein containing an RNA recognition motif (RRM), which was overexpressed in diffuse-type gastric cancer. Cancer Sci 95: 430-435, 2004.
33. Jolly C and Morimoto RI: Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 92: 1564-1572, 2000.
34. Garrido C, Gurbuxani S, Ravagnan L and Kroemer G: Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun 286: 433-442, 2001.
35. Ciocca DR, Clerk GM, Tandon AK, Fuqua SA, Welch WJ and McGuire WL: Heat shock protein 70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst 85: 570-574, 1993.
36. Malusecka E, Zborek A, Krzyzowska-Gruca S and Krawczyk Z: Expression of heat shock proteins HSP70 and HSP27 in primary non-small cell lung carcinomas. An immunohistochemical study. Anticancer Res 21: 1015-1021, 2001.
37. Kaur J and Ralhan R: Differential expression of 70-kDa heat shock-protein in human oral tumorgenesis. Int J cancer 63: 774-779, 1995.
38. Comford PA, Dodson AR, Parsons KF, et al: Heat hock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 60: 7099-7105, 2000.
39. Park CS, Joo IS, Song SY, Kim DS and Lee JH: An immunohistochemical analysis of heat shock protein 70, p53, and estrogen receptor status in carcinoma of the uterine cervix. Gynecol Oncol 74: 53-60, 1999.
40. Ross TS, Bernard OA, Berger R and Gilliland DG: Fusion of huntingtin interacting protein 1 to platelet-derived growth factor β receptor (PDGFβR) in chronic myelomonocytic leukemia with t (5; 7)(q33; q11.2). Blood 91: 4419-4426, 1998.
41. Rao DS, Hyun TS, Kumar PD, et al: Huntingtin interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J Clin Invest 110: 351-560, 2002.